BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35514249)

  • 1. Early detection of hepatocellular carcinoma: roadmap for improvement.
    Melendez-Torres J; Singal AG
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):621-632. PubMed ID: 35514249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular Carcinoma Surveillance Patterns and Outcomes in Patients With Cirrhosis.
    Daher D; Seif El Dahan K; Cano A; Gonzales M; Ransom C; Jaurez E; Carranza O; Quirk L; Morgan T; Gopal P; Patel MS; Lieber S; Louissaint J; Cotter TG; VanWagner LB; Yang JD; Parikh ND; Yopp A; Rich NE; Singal AG
    Clin Gastroenterol Hepatol; 2024 Feb; 22(2):295-304.e2. PubMed ID: 37573986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis.
    Atiq O; Tiro J; Yopp AC; Muffler A; Marrero JA; Parikh ND; Murphy C; McCallister K; Singal AG
    Hepatology; 2017 Apr; 65(4):1196-1205. PubMed ID: 27775821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis.
    Tayob N; Christie I; Richardson P; Feng Z; White DL; Davila J; Corley DA; Kanwal F; El-Serag HB
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1886-1893.e5. PubMed ID: 30557738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States.
    Kim NJ; Rozenberg-Ben-Dror K; Jacob DA; Rich NE; Singal AG; Aby ES; Yang JD; Nguyen V; Pillai A; Fuchs M; Moon AM; Shroff H; Agarwal PD; Perumalswami P; Chandna S; Zhou K; Patel YA; Latt NL; Wong R; Duarte-Rojo A; Lindenmeyer CC; Frenette C; Ge J; Mehta N; Yao F; Benhammou JN; Bloom PP; Leise M; Kim HS; Levy C; Barnard A; Khalili M; Ioannou GN
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):183-193. PubMed ID: 32927050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma.
    Song P; Tang Q; Feng X; Tang W
    Scand J Clin Lab Invest Suppl; 2016; 245():S70-6. PubMed ID: 27438343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies.
    Tayob N; Corley DA; Christie I; Almers L; Rahal AK; Richardson P; White DL; Davila J; Kanwal F; El-Serag HB
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1443-1450.e6. PubMed ID: 32768590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.
    Parikh ND; Singal AG; Hutton DW; Tapper EB
    Am J Gastroenterol; 2020 Oct; 115(10):1642-1649. PubMed ID: 32530829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis.
    Worland T; Harrison B; Delmenico L; Dowling D
    J Gastrointest Cancer; 2018 Dec; 49(4):476-480. PubMed ID: 28920172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-Fetoprotein Detection of Hepatocellular Carcinoma Leads to a Standardized Analysis of Dynamic AFP to Improve Screening Based Detection.
    Bird TG; Dimitropoulou P; Turner RM; Jenks SJ; Cusack P; Hey S; Blunsum A; Kelly S; Sturgeon C; Hayes PC; Bird SM
    PLoS One; 2016; 11(6):e0156801. PubMed ID: 27308823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis.
    Singal AG; Tayob N; Mehta A; Marrero JA; Jin Q; Lau J; Parikh ND
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):953-955.e2. PubMed ID: 33864933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review.
    Shahini E; Pasculli G; Solimando AG; Tiribelli C; Cozzolongo R; Giannelli G
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System.
    Tayob N; Richardson P; White DL; Yu X; Davila JA; Kanwal F; Feng Z; El-Serag HB
    BMC Med Res Methodol; 2018 Jan; 18(1):1. PubMed ID: 29301497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular Carcinoma Surveillance: Evidence-Based Tailored Approach.
    Koo E; Singal AG
    Surg Oncol Clin N Am; 2024 Jan; 33(1):13-28. PubMed ID: 37945138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.
    Singal AG; Tayob N; Mehta A; Marrero JA; El-Serag H; Jin Q; Saenz de Viteri C; Fobar A; Parikh ND
    Hepatology; 2022 Mar; 75(3):541-549. PubMed ID: 34618932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis.
    Kim MN; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim DY
    Scand J Gastroenterol; 2019 Oct; 54(10):1283-1290. PubMed ID: 31593481
    [No Abstract]   [Full Text] [Related]  

  • 18. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.
    Chang TS; Wu YC; Tung SY; Wei KL; Hsieh YY; Huang HC; Chen WM; Shen CH; Lu CH; Wu CS; Tsai YH; Huang YH
    Am J Gastroenterol; 2015 Jun; 110(6):836-44; quiz 845. PubMed ID: 25869392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.
    Kim HA; Kim KA; Choi JI; Lee JM; Lee CH; Kang TW; Ku YM; Lee SL; Park YS; Yoon JH; Kim SH; Choi MH
    BMC Cancer; 2017 Dec; 17(1):877. PubMed ID: 29268722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients.
    Demirtas CO; Gunduz F; Tuney D; Baltacioglu F; Kani HT; Bugdayci O; Alahdab YO; Ozdogan OC
    Eur J Gastroenterol Hepatol; 2020 Apr; 32(4):517-523. PubMed ID: 31524775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.